Journal of Immunology Publishes Study of Cleveland BioLabs' Drug CBLB502 in ... - MarketWatch (press release) PDF Print
MarketWatch (press release)
The study, conducted by scientists at Cleveland Clinic, Roswell Park Cancer Institute and Hokkaido University, analyzed the ability of CBLB502 to attenuate injury in a murine model of acute ischemic renal failure, a potentially fatal and poorly

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.